These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 29482752)

  • 1. Non-
    Kalshetty A; Basu S
    PET Clin; 2018 Apr; 13(2):239-248. PubMed ID: 29482752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDG-PET Assessment of Other Gynecologic Cancers.
    Faria S; Devine C; Viswanathan C; Javadi S; Korivi BR; Bhosale PR
    PET Clin; 2018 Apr; 13(2):203-223. PubMed ID: 29482750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative Assessment of Gynecologic Malignancies.
    Tripathy S; Parida GK; Kumar R
    PET Clin; 2018 Apr; 13(2):269-288. PubMed ID: 29482754
    [No Abstract]   [Full Text] [Related]  

  • 4. The Role of PET Imaging in Gynecologic Radiation Oncology.
    Rao YJ; Grigsby PW
    PET Clin; 2018 Apr; 13(2):225-237. PubMed ID: 29482751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional images reflect aggressiveness of endometrial carcinoma: estrogen receptor expression combined with 18F-FDG PET.
    Tsujikawa T; Yoshida Y; Kudo T; Kiyono Y; Kurokawa T; Kobayashi M; Tsuchida T; Fujibayashi Y; Kotsuji F; Okazawa H
    J Nucl Med; 2009 Oct; 50(10):1598-604. PubMed ID: 19759112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uterine tumors: pathophysiologic imaging with 16alpha-[18F]fluoro-17beta-estradiol and 18F fluorodeoxyglucose PET--initial experience.
    Tsujikawa T; Yoshida Y; Mori T; Kurokawa T; Fujibayashi Y; Kotsuji F; Okazawa H
    Radiology; 2008 Aug; 248(2):599-605. PubMed ID: 18539894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of
    Narayanan P; Sahdev A
    Br J Radiol; 2017 Nov; 90(1079):20170283. PubMed ID: 28830238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional oestrogen receptor α imaging in endometrial carcinoma using 16α-[¹⁸F]fluoro-17β-oestradiol PET.
    Tsujikawa T; Yoshida Y; Kiyono Y; Kurokawa T; Kudo T; Fujibayashi Y; Kotsuji F; Okazawa H
    Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):37-45. PubMed ID: 20717823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET.
    Torizuka T; Kanno T; Futatsubashi M; Okada H; Yoshikawa E; Nakamura F; Takekuma M; Maeda M; Ouchi Y
    J Nucl Med; 2003 Jul; 44(7):1051-6. PubMed ID: 12843219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FES and 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors: correlation with immunohistochemical analysis.
    Zhao Z; Yoshida Y; Kurokawa T; Kiyono Y; Mori T; Okazawa H
    J Nucl Med; 2013 Apr; 54(4):499-506. PubMed ID: 23471314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
    Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
    Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16α-18F-fluoro-17β-estradiol PET/CT.
    van Kruchten M; de Vries EF; Arts HJ; Jager NM; Bongaerts AH; Glaudemans AW; Hollema H; de Vries EG; Hospers GA; Reyners AK
    J Nucl Med; 2015 Jan; 56(1):50-5. PubMed ID: 25476534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normal Variants and Pitfalls Encountered in PET Assessment of Gynecologic Malignancies.
    Yu JQ; Doss M; Alpaugh RK
    PET Clin; 2018 Apr; 13(2):249-268. PubMed ID: 29482753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinctive FDG and FES accumulation pattern of two tamoxifen-treated patients with endometrial hyperplasia.
    Tsujikawa T; Okazawa H; Yoshida Y; Mori T; Kobayashi M; Tsuchida T; Fujibayashi Y
    Ann Nucl Med; 2008 Jan; 22(1):73-7. PubMed ID: 18250990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gynecological cancers.
    Avril N; Gourtsoyianni S; Reznek R
    Methods Mol Biol; 2011; 727():171-89. PubMed ID: 21331934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET Imaging for Gynecologic Malignancies.
    Friedman SN; Itani M; Dehdashti F
    Radiol Clin North Am; 2021 Sep; 59(5):813-833. PubMed ID: 34392921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients.
    Koleva-Kolarova RG; Greuter MJ; van Kruchten M; Vermeulen KM; Feenstra T; Buskens E; Glaudemans AW; de Vries EF; de Vries EG; Hospers GA; de Bock GH
    Br J Cancer; 2015 May; 112(10):1617-25. PubMed ID: 25880006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Present and future role of FDG-PET/CT imaging in the management of gynecologic malignancies.
    Kitajima K; Ebina Y; Sugimura K
    Jpn J Radiol; 2014 Jun; 32(6):313-23. PubMed ID: 24744135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic Tumor Volume on 18F-FDG PET/CT Improves Preoperative Identification of High-Risk Endometrial Carcinoma Patients.
    Husby JA; Reitan BC; Biermann M; Trovik J; Bjørge L; Magnussen IJ; Salvesen ØO; Salvesen HB; Haldorsen IS
    J Nucl Med; 2015 Aug; 56(8):1191-8. PubMed ID: 26045311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positron emission tomography in gynecological malignancies.
    Kumar R; Chauhan A; Jana S; Dadparvar S
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):1033-44. PubMed ID: 16831075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.